Latest News and Press Releases
Want to stay updated on the latest news?
-
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
-
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq:...
-
LEXINGTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
-
LEXINGTON, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
-
-- Initiated Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis ---- Established strategic mRNA vaccines partnership with Sanofi Pasteur ---- Completed initial public offering...
-
LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...